Haemonetics Co. (NYSE:HAE) Insider Stewart W. Strong Sells 733 Shares of Stock

Haemonetics Co. (NYSE:HAE) insider Stewart W. Strong sold 733 shares of the stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $96.04, for a total transaction of $70,397.32. Following the completion of the transaction, the insider now owns 15,608 shares in the company, valued at $1,498,992.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Haemonetics Stock Up 1.0 %

Shares of NYSE HAE traded up $0.93 during mid-day trading on Friday, reaching $95.73. 212,897 shares of the company’s stock were exchanged, compared to its average volume of 482,174. The company has a current ratio of 2.56, a quick ratio of 1.50 and a debt-to-equity ratio of 0.83. The business has a fifty day simple moving average of $86.31 and a 200 day simple moving average of $83.31. Haemonetics Co. has a twelve month low of $70.74 and a twelve month high of $97.97. The firm has a market capitalization of $4.86 billion, a price-to-earnings ratio of 41.81, a PEG ratio of 1.72 and a beta of 0.34.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $0.90 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.02. Haemonetics had a net margin of 8.98% and a return on equity of 22.25%. The company had revenue of $343.00 million during the quarter, compared to analysts’ expectations of $329.53 million. During the same quarter in the prior year, the company earned $0.77 earnings per share. The business’s quarterly revenue was up 12.7% compared to the same quarter last year. As a group, equities analysts expect that Haemonetics Co. will post 4.6 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on HAE. Barrington Research upped their target price on shares of Haemonetics from $105.00 to $107.00 and gave the company an “outperform” rating in a research report on Friday, May 10th. TheStreet lowered Haemonetics from a “b-” rating to a “c+” rating in a research note on Thursday, February 29th. Needham & Company LLC restated a “hold” rating on shares of Haemonetics in a research report on Friday, May 10th. JMP Securities upped their price target on Haemonetics from $115.00 to $125.00 and gave the company a “market outperform” rating in a research note on Friday, May 10th. Finally, StockNews.com cut shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $108.67.

Institutional Trading of Haemonetics

Hedge funds and other institutional investors have recently modified their holdings of the company. TFO Wealth Partners LLC grew its holdings in shares of Haemonetics by 29,450.0% in the 4th quarter. TFO Wealth Partners LLC now owns 591 shares of the medical instruments supplier’s stock valued at $51,000 after acquiring an additional 589 shares in the last quarter. Group One Trading L.P. acquired a new position in shares of Haemonetics during the 3rd quarter worth approximately $55,000. Covestor Ltd raised its stake in shares of Haemonetics by 184.8% during the 1st quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier’s stock worth $58,000 after purchasing an additional 438 shares in the last quarter. EntryPoint Capital LLC acquired a new stake in shares of Haemonetics in the 1st quarter valued at approximately $86,000. Finally, Parkside Financial Bank & Trust grew its stake in shares of Haemonetics by 17.4% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,054 shares of the medical instruments supplier’s stock valued at $90,000 after buying an additional 156 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.